# US 2013/0280283 A1 · Combination of vaccination and inhibition of mhc class i restricted antigen presentation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280283 A1
- Document ID: US20130280283A1
- Status: Published application
- Kind: A1
- Application number: 13/824,502
- Filed: 2011-12-27
- Published: 2013-10-24
- Earliest claimed: 2010-12-29
- Assignees: CureVac AG
- Inventors: Christina Lorenz; Mariola Fotin-Mleczek; Karl-Josef Kallen
- Web page: https://patentgrep.com/patent/US20130280283A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55516: {Proteins; Peptides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (MHC) class I restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination. The present invention also provides kit of parts comprising the inventive vaccine/inhibitor combination, preferably in different parts of the kit, e.g. for prior, concurrent or subsequent administration of the different parts. Additionally the invention relates to a pharmaceutical composition comprising the inventive vaccine/inhibitor combination to further improve the immune response against tumour cells and infected cells having lost the capability of MHC class I restricted antigen presentation.

## Claims

### Claim 1

Vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of MHC class I restricted antigen presentation.

### Claim 2 (depends on 1)

Vaccine/inhibitor combination according to claim 1, wherein the inhibitor and the vaccine are to be administered to the patient in a time staggered manner.

### Claim 3 (depends on 1)

Vaccine/inhibitor combination according to claim 1, wherein the inhibitor and the vaccine are to be administered to the patient at different administration sites.

### Claim 4 (depends on 1)

Vaccine/inhibitor combination according to claim 1, wherein the inhibitor is encoded by a nucleic acid.

### Claim 5 (depends on 4)

Vaccine/inhibitor combination according to claim 4, wherein the inhibitor is encoded by an mRNA.

### Claim 6 (depends on 1)

Vaccine/inhibitor combination according to claim 1, wherein the vaccine is a nucleic acid coding for at least one antigen.

### Claim 7 (depends on 6)

Vaccine/inhibitor combination according to claim 6, wherein the vaccine is an mRNA coding for at least one antigen.

### Claim 8 (depends on 1)

Vaccine/inhibitor combination according to claim 1, wherein the combination does not comprise an MHC class I heavy chain, and/or a β2m protein, and/or a fusion protein comprising an MHC class I heavy chain or a β2m protein, and/or a nucleic acid or a vector encoding any such protein or fusion protein.

### Claim 9 (depends on 1)

Vaccine/inhibitor combination according to claim 1, wherein the combination does not comprise an antigen presenting cell, e.g. a dendritic cell.

### Claim 10 (depends on 1)

Vaccine/inhibitor combination according to claim 1, wherein the combination is formulated as a kit of parts composition, wherein the inhibitor and the vaccine form different parts of such a kit.

### Claim 11 (depends on 1)

Vaccine/inhibitor combination according to claim 1, wherein the vaccine/inhibitor composition further comprises an additional vaccine.

### Claim 12 (depends on 10)

Vaccine/inhibitor combination according to claim 10, wherein the additional vaccine is a separate part of the kit of parts or a part of the kit of parts comprising the inhibitor of the vaccine/inhibitor composition.

### Claim 13 (depends on 10)

Vaccine/inhibitor combination according to claim 10, wherein the additional vaccine and the inhibitor of the vaccine/inhibitor combination are to be administered at the same time and/or the same administration site.

### Claim 14 (depends on 10)

Vaccine/inhibitor combination according to claim 10, wherein the additional vaccine and the inhibitor of the vaccine/inhibitor combination are to be administered prior, concurrent or subsequent to the vaccine of the vaccine/inhibitor combination.

### Claim 15 (depends on 1)

Pharmaceutical composition comprising a vaccine and an inhibitor of MHC class I restricted antigen presentation as defined according to claim 1.

### Claim 16 (depends on 15)

Pharmaceutical composition according to claim 15, wherein the pharmaceutical composition is formulated as a kit of parts composition, wherein the inhibitor, the vaccine and/or the optional additional vaccine form different parts of such a kit of parts.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method for the treatment of cancer or infectious diseases, which are associated with impaired antigen presentation on MHC class I molecules comprising administering to a subject in need thereof a therapeutically effective amount of at least one vaccine/inhibitor combination according to claim 1.

### Claim 19 (depends on 15)

A method for the treatment of cancer or infectious diseases, which are associated with impaired antigen presentation on MHC class I molecules comprising administering to a subject in need thereof a therapeutically effective amount of at least one pharmaceutical composition according to claim 15.
